- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
BMS used navy/grey (not black) inverted triangles on a UK corporate products page. No breach of Clause 4.10 (not promotional), but breach…
A pharmacist alleged a Sanofi-Aventis rep misrepresented ADA/EASD guidance for Lantus and confused Acomplia study data/positioning. Panel couldn’t determine what was said…
Abbott invited renal physicians to a Zemplar advisory board with a £500 honorarium. Appeal Board said it was a genuine advisory board,…
A Pulse ‘Advertisement Feature’ for Levemir wasn’t disguised promotion, but weight-loss messaging from an uncontrolled observational study was ruled misleading, ambiguous and…
Takeda sent GPs a cost-saving leaflet referencing a PCT repeatedly but with minimal company identification. The Panel ruled it misleading/disguised promotion and…
A GP complained a Cymbalta leavepiece did not place the non-proprietary name (duloxetine) immediately adjacent to the most prominent brand name. The…
A PCT medicines management head alleged a Yahoo.com Enbrel ad was UK direct-to-consumer promotion. Panel found the site and ad were US-directed…
Complaint alleged a Novo Nordisk corporate ad in a diabetes magazine amounted to indirect direct-to-public promotion. Panel found it might prompt discussion…
Roche’s NeoRecormon congress panel/brochure used a “24% dose reduction vs darbepoetin alfa” and Hb target messaging based on retrospective data. PMCPA found…
Daiichi-Sankyo reported that an Olmetec advert previously ruled in breach reappeared after an undertaking not to use it. Panel found failures to…
A pharmacist challenged Sun Pharma’s email claim that ready-to-administer gemcitabine “minimise[s] risk”. PMCPA ruled the claim misleading and not substantiated (Clauses 7.2,…
Complaint about a Gilenya advertisement in a lay publication. PMCPA concluded the matter was outwith the scope of the ABPI Code (2012).…
A member of the public complained about clinical trial disclosure for Halaven. The PMCPA ruled the matter was outwith the scope of…
A PR agency working for Janssen-Cilag offered journalists £200 to attend a NICE appeal hearing. Janssen-Cilag said it was unaware, but the…
Bonviva materials compared monthly vs weekly dosing and claimed 71% patient preference versus alendronate. PMCPA ruled the comparison misleading because Bonviva’s hip-fracture…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.